NCT07289477招募中1 期
A Phase I/III Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Putamen Transplantation of NouvNeu001 Injection for Multiple System Atrophy
iRegene Therapeutics Co., Ltd.1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2026年1月5日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Incidence and severity of Adverse Events as Assessed by CTCAE V5.0
研究概览
简要总结
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged between 30 and 70 years (inclusive), regardless of gender.
- •The subject understands and agrees to comply with the study procedures and voluntarily provides written informed consent.
- •Diagnosed with pathologically confirmed, clinically established, or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria.
- •Current treatments for core MSA symptoms are inadequately controlled.
- •The duration of MSA-related motor symptoms (parkinsonism and/or cerebellar ataxia) is no more than 5 years.
- •Ability to walk without human assistance, defined as being able to take at least 10 steps; the use of assistive devices (e.g., a walker or cane) is permitted.
- •Life expectancy of at least 3 years.
- •The subject agrees not to participate in any other clinical studies for 24 months following the investigational product administration.
排除标准
- •Neurological diseases/disorders other than Multiple System Atrophy, such as Parkinson's disease, Dementia with Lewy Bodies, Essential Tremor, Progressive Supranuclear Palsy, Spinocerebellar Ataxia, Hereditary Spastic Paraplegia, Corticobasal Degeneration, Vascular Parkinsonism, Normal Pressure Hydrocephalus, or Drug-induced/Postencephalitic Parkinsonism.
- •Diagnosis of dementia.
- •Previous or current receipt of other disease-modifying therapies, or participation in clinical trials of other new drugs or novel therapies.
- •Use of medications within the past 3 months that may affect Parkinsonian symptoms, autonomic function, or the evaluation of safety.
- •Presence of clinically significant or unstable medical or surgical conditions that may preclude the safe completion of the treatment or confound the treatment outcomes.
- •History of or undergoing treatment for recurrent stroke.
- •Screening brain MRI shows other significant pathological findings, including but not limited to: cerebral hemorrhage, acute cerebral infarction, aneurysm, vascular malformation, infectious lesions, brain tumors, or other space-occupying lesions (meningiomas or arachnoid cysts with a maximum diameter of less than 1 cm do not warrant exclusion).
- •Subjects meeting any of the following criteria indicating advanced disease:
- •Speech impairment defined by a score of ≥3 on UMSARS Item
- •Swallowing impairment defined by a score of ≥3 on UMSARS Item
- •Walking impairment defined by a score of ≥3 on UMSARS Item
- •Occurrence of falls more than once per week, defined by a score of ≥3 on UMSARS Item
- •History of current substance abuse and/or alcohol abuse (within 12 months prior to screening).
- •Known allergy to the investigational product(s); or history of allergy to antibiotics or other drugs.
- •Positive screening results for active viral infection, including Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg), Hepatitis B Core Antibodies, or Hepatitis C Virus (HCV).
- •Severe hepatic insufficiency, renal insufficiency, or severe cardiac insufficiency:
- •Severe hepatic insufficiency: ALT ≥ 2.0 × upper limit of normal (ULN) or AST ≥ 2.0 × ULN.
- •Severe renal insufficiency: Serum creatinine ≥ 1.5 × ULN or estimated Glomerular Filtration Rate (eGFR) < 40 mL/min/1.73 m².
- •Severe cardiac insufficiency: New York Heart Association (NYHA) Class 3 or
- •History of thrombocytopenia within the past three months, other bleeding disorders, or current receipt of anticoagulant therapy (excluding aspirin at a dose ≤ 100 mg per day).
- •Pregnancy, lactation, or planning pregnancy.
- •History of Bipolar Disorder, Major Depressive Disorder, Schizophrenia, or other psychotic disorders.
- •Subjects judged by the investigator to have suicidal ideation at screening, or a suicide attempt within 6 months prior to screening.
- •Contraindications for surgery (e.g., implantation of cochlear implants, pacemakers, defibrillators, history of stereotactic ablation, previous implantation of unilateral/bilateral similar products) or history of other surgeries within the past 6 months deemed by the investigator to potentially affect this trial, or other neurosurgical contraindications.
- •Clinically significant cardiac disease defined as: myocardial infarction, NYHA Class III or IV heart failure, uncontrolled coronary spasm, severe uncontrolled ventricular arrhythmia, or evidence of acute ischemia or abnormal conduction system on ECG within 6 months prior to enrollment.
- •Diagnosis of malignancy.
- •Family history of congenital or inherited immunodeficiency disorders.
- •Considered by the investigator to have poor compliance.
- •Any other significant disease or condition that, in the investigator's judgment, may jeopardize the subject's safety or interfere with the study assessments.
研究组 & 干预措施
NouvNeu001
Experimental
During the enrollment phase for the low-dose cohort, 3 participants will be randomized to the experimental arm to receive a single administration of NouvNeu001 Injection.
干预措施: Human Dopaminergic Progenitor Cells (Biological)
control
No Intervention
During the enrollment phase for the low-dose cohort, 3 participants will be randomized to the control arm, which will not receive NouvNeu001 Injection.
结局指标
主要结局
Incidence and severity of Adverse Events as Assessed by CTCAE V5.0
时间窗: 52 weeks post-transplant
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
次要结局
- Change from baseline in the UMSARS total score (Part I + Part II) at Weeks 13, 26, and 52.(Weeks 13, 26, and 52 post-transplant)
- Change from baseline in the UMSARS Part I score at Weeks 13, 26, and 52.(Weeks 13, 26, and 52 post-transplant)
- Change from baseline in the UMSARS Part II score at Weeks 13, 26, and 52.(Weeks 13, 26, and 52 post-transplant)
- Change from baseline in dopaminergic metabolism of the basal ganglia at Week 52, as measured by DAT PET imaging.(Weeks 52 post-transplant)
- Change from baseline in the CGI-S score at Weeks 13, 26, and 52.(Weeks 13, 26, and 52 post-transplant)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerNCT07282509CSPC ZhongQi Pharmaceutical Technology Co., Ltd.116
招募中
1 期
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.CRCNCT07283367Hansoh BioMedical R&D Company502
尚未招募
2 期
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
尚未招募
1 期
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNCT07279428Sichuan Baili Pharmaceutical Co., Ltd.33
招募中
1 期
A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with relapsed and refractory B-cell malignancies (CARLOTTA01)2022-502831-20-00Technische Universitat Dresden16